Product Description
For relapsed and refractory MDS, chronic myelomonocytic leukemia (CMML), and AML (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03614728)
Mechanisms of Action: PRMT5 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, France, Netherlands, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Meteor 1 | P1 |
Completed |
Lymphoma, Non-Hodgkin |
2023-08-30 |